A new study could prove to be a major step toward detecting the brain disease chronic traumatic encephalopathy, or CTE, while patients are still alive. That would be a crucial breakthrough for researchers who have struggled to find ways to treat a disease that can currently only be diagnosed after death.
In the new research led by scientists at Boston University and Arizona-based Banner Health, researchers say they may have found a way to identify CTE, which is tied to repetitive head impacts and has been heavily linked to football, through a blood test.
And while there’s still a lot of work to do before the findings are applied widely, the new study published Thursday in The Journal of the American Medical Association could potentially be a big moment in CTE research.
“This is a game changer,” Michael Alosco, co-director of clinical research at the BU CTE Center, said in a statement. “If future studies validate these findings, this blood test will allow us to detect CTE with a high level of accuracy and open the doors to clinical trials and treatment.”
Researchers looked at 21 former football players who had their blood drawn while they were alive and then donated their brains to the BU CTE Center Brain Bank after they died. Eighteen of the former players had CTE, including 16 with high-stage CTE.
For players with high-stage CTE, researchers tested their blood and found it contained a much higher level of a protein that’s also been associated with Alzheimer’s disease: endogenously cleaved microtubule-binding region tau, or eMTBR-tau.
It did not detect those same levels in people who had low-stage or no CTE.
“So when eMTBR-tau was being investigated in the context of Alzheimer’s disease and people were finding that it was really associated with that tau pathology, that really was the motivator for looking at it in the context of CTE,” said Annalise Miner, a BU researcher who is one of the study’s authors.
A separate study also published in JAMA found elevated levels of blood plasma eMTBR-tau243 in people with CTE.
Miner called the findings a great first step.
“Especially of CTE and the presence of Alzheimer’s disease, we see really high levels,” Miner said. “So, it is accurate for finding that high level of pathology, I would say.”
The study has the largest sample of participants who had their blood collected while they were alive and then had an available autopsy. And while it’s not yet a validated test, Miner said the next step is to look at it in a larger cohort.
“But it’s really important because you can’t have something like a clinical trial without being able to measure a pathology during life,” she said. “So with CTE, we can’t currently measure it. So having that biomarker will help the acceleration of clinical trials and hopefully treatments in the future.”